Significados de remit ms em inglês

Movectro was intended to be used for the treatment of relapsing- remitting MS.

Biogen also markets Avonex and Tysabri to treat relapsing- remitting MS, the most common kind of MS.

Materials and methods: Thirty patients with relapsing- remitting MS and 25 healthy control subjects underwent magnetic resonance imaging.

Conclusions: Our 2-year longitudinal study showed no effect of glatiramer therapy on cognitive function in relapsing- remitting MS.

Conclusion: Loss of brain parenchymal volume in patients with relapsing- remitting MS is predominantly confined to white matter.

Two randomized double-blind placebo-controlled trials of beta-interferon in mildly disabled patients with relapsing remitting MS have been published.

Second, these items were administered to 160 people with relapsing- remitting MS. Standard psychometric techniques were used to develop a scale.

Significant atrophy was reported to occur within 9 to 12 months in relapsing remitting MS.

We previously reported that oral myelin tolerization of relapsing- remitting MS patients resulted in fewer attacks, as compared to a placebo-fed group.

Such patients have initial relapsing- remitting MS, but then begin to have progressive neurologic decline between acute attacks without definite periods of remission.

Trials of the drug, CDP323, began this week and are to cover 200 patients with relapsing- remitting MS.

Mapi's drug is being developed to treat relapsing- remitting MS - marked by relapses that last at least 24 hours, followed by a remission.

Conclusions and relevance: Among patients with relapsing- remitting MS, nonmyeloablative hematopoietic stem cell transplantation was associated with improvement in neurological disability and other clinical outcomes.

In relapsing- remitting MS patients, we found elevated anti-SNO-cysteine Ab at times of relapse and normal values in most patients judged to be in remission.

This review examines if there is a trend in the ARR for relapsing- remitting MS patients (RRMS) over time and if so, why.

Further screening was carried out in samples from 654 relapsing- remitting MS patients, 100 primary progressive MS patients, and 661 controls.